

# UC Davis

## UC Davis Previously Published Works

### Title

Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

### Permalink

<https://escholarship.org/uc/item/5m7965q3>

### Journal

npj Breast Cancer, 4(1)

### ISSN

2374-4677

### Authors

Petkov, Valentina I

Miller, Dave P

Howlader, Nadia

et al.

### Publication Date

2018

### DOI

10.1038/s41523-018-0069-3

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

## AUTHOR CORRECTION OPEN

## Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

Valentina I Petkov<sup>1</sup>, Dave P Miller<sup>2</sup>, Nadia Howlader<sup>1</sup>, Nathan Gliner<sup>2</sup>, Will Howe<sup>3</sup>, Nicola Schussler<sup>3</sup>, Kathleen Cronin<sup>1</sup>, Frederick L Baehner<sup>2,4</sup>, Rosemary Cress<sup>5</sup>, Dennis Deapen<sup>6</sup>, Sally L Glaser<sup>7,8</sup>, Brenda Y Hernandez<sup>9</sup>, Charles F Lynch<sup>10</sup>, Lloyd Mueller<sup>11</sup>, Ann G Schwartz<sup>12</sup>, Stephen M Schwartz<sup>13</sup>, Antoinette Stroup<sup>14,15</sup>, Carol Sweeney<sup>16</sup>, Thomas C Tucker<sup>17</sup>, Kevin C Ward<sup>18</sup>, Charles Wiggins<sup>19</sup>, Xiao-Cheng Wu<sup>20</sup>, Lynne Penberthy<sup>1</sup> and Steven Shak<sup>2</sup>

*npj Breast Cancer* (2018)4:17; doi:10.1038/s41523-018-0069-3

**Correction to:** *npj Breast Cancer*; <https://doi.org/10.1038/npjbcancer.2016.17>, Published online 8 June 2016

In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes ( $n = 2,617$ ) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the Article stated “Patients with HR+, HER2-positive, node-negative...” this has been changed to “Patients with HR+,

HER2-negative, node-negative...”. This has been corrected in the PDF and HTML versions of this paper.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018

<sup>1</sup>National Cancer Institute, Bethesda, MD, USA; <sup>2</sup>Genomic Health, Inc., Redwood City, CA, USA; <sup>3</sup>IMS, Inc., Calverton, MD, USA; <sup>4</sup>University of California, San Francisco, CA, USA; <sup>5</sup>Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA; <sup>6</sup>University of Southern California, Los Angeles, CA, USA; <sup>7</sup>Cancer Prevention Institute of California, Fremont, CA, USA; <sup>8</sup>Stanford Cancer Institute, Stanford, CA, USA; <sup>9</sup>University of Hawaii Cancer Center, Honolulu, HI, USA; <sup>10</sup>Department of Epidemiology, University of Iowa, Iowa City, IA, USA; <sup>11</sup>Connecticut Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA; <sup>12</sup>Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; <sup>13</sup>Cancer Surveillance System, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>14</sup>Rutgers School of Public Health, Piscataway, NJ, USA; <sup>15</sup>Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>16</sup>Utah Cancer Registry, Department of Internal Medicine, and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; <sup>17</sup>University of Kentucky, Markey Cancer Center, Lexington, KY, USA; <sup>18</sup>Emory University, Atlanta, GA, USA; <sup>19</sup>New Mexico Tumor Registry, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA and <sup>20</sup>Louisiana State University Health Sciences Center, New Orleans, LA, USA  
Correspondence: Valentina I Petkov (valentina.petkov@nih.gov)

Published online: 06 July 2018